High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis

Hepatotoxicity is one of the most cited reasons for withdrawal of approved drugs from the market. The use of nonclinically relevant in vitro and in vivo testing systems contributes to the high attrition rates. Recent advances in differentiating human induced pluripotent stem cells (hiPSCs) into pure...

Full description

Bibliographic Details
Main Authors: Arvind Pradip, Daniella Steel, Susanna Jacobsson, Gustav Holmgren, Magnus Ingelman-Sundberg, Peter Sartipy, Petter Björquist, Inger Johansson, Josefina Edsbagge
Format: Article
Language:English
Published: Hindawi Limited 2016-01-01
Series:Stem Cells International
Online Access:http://dx.doi.org/10.1155/2016/2475631
id doaj-8b203484bced439b8882919f567af0b1
record_format Article
spelling doaj-8b203484bced439b8882919f567af0b12020-11-24T22:51:22ZengHindawi LimitedStem Cells International1687-966X1687-96782016-01-01201610.1155/2016/24756312475631High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and PhospholipidosisArvind Pradip0Daniella Steel1Susanna Jacobsson2Gustav Holmgren3Magnus Ingelman-Sundberg4Peter Sartipy5Petter Björquist6Inger Johansson7Josefina Edsbagge8Takara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, SwedenTakara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, SwedenTakara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, SwedenTakara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, SwedenDepartment of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, 171 77 Stockholm, SwedenTakara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, SwedenTakara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, SwedenDepartment of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, 171 77 Stockholm, SwedenTakara Bio Europe AB (Former Cellectis AB/Cellartis AB), Arvid Wallgrens Backe 20, 413 46 Göteborg, SwedenHepatotoxicity is one of the most cited reasons for withdrawal of approved drugs from the market. The use of nonclinically relevant in vitro and in vivo testing systems contributes to the high attrition rates. Recent advances in differentiating human induced pluripotent stem cells (hiPSCs) into pure cultures of hepatocyte-like cells expressing functional drug metabolizing enzymes open up possibilities for novel, more relevant human cell based toxicity models. The present study aimed to investigate the use of hiPSC derived hepatocytes for conducting mechanistic toxicity testing by image based high content analysis (HCA). The hiPSC derived hepatocytes were exposed to drugs known to cause hepatotoxicity through steatosis and phospholipidosis, measuring several endpoints representing different mechanisms involved in drug induced hepatotoxicity. The hiPSC derived hepatocytes were benchmarked to the HepG2 cell line and generated robust HCA data with low imprecision between plates and batches. The different parameters measured were detected at subcytotoxic concentrations and the order of which the compounds were categorized (as severe, moderate, mild, or nontoxic) based on the degree of injury at isomolar concentration corresponded to previously published data. Taken together, the present study shows how hiPSC derived hepatocytes can be used as a platform for screening drug induced hepatotoxicity by HCA.http://dx.doi.org/10.1155/2016/2475631
collection DOAJ
language English
format Article
sources DOAJ
author Arvind Pradip
Daniella Steel
Susanna Jacobsson
Gustav Holmgren
Magnus Ingelman-Sundberg
Peter Sartipy
Petter Björquist
Inger Johansson
Josefina Edsbagge
spellingShingle Arvind Pradip
Daniella Steel
Susanna Jacobsson
Gustav Holmgren
Magnus Ingelman-Sundberg
Peter Sartipy
Petter Björquist
Inger Johansson
Josefina Edsbagge
High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis
Stem Cells International
author_facet Arvind Pradip
Daniella Steel
Susanna Jacobsson
Gustav Holmgren
Magnus Ingelman-Sundberg
Peter Sartipy
Petter Björquist
Inger Johansson
Josefina Edsbagge
author_sort Arvind Pradip
title High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis
title_short High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis
title_full High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis
title_fullStr High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis
title_full_unstemmed High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis
title_sort high content analysis of human pluripotent stem cell derived hepatocytes reveals drug induced steatosis and phospholipidosis
publisher Hindawi Limited
series Stem Cells International
issn 1687-966X
1687-9678
publishDate 2016-01-01
description Hepatotoxicity is one of the most cited reasons for withdrawal of approved drugs from the market. The use of nonclinically relevant in vitro and in vivo testing systems contributes to the high attrition rates. Recent advances in differentiating human induced pluripotent stem cells (hiPSCs) into pure cultures of hepatocyte-like cells expressing functional drug metabolizing enzymes open up possibilities for novel, more relevant human cell based toxicity models. The present study aimed to investigate the use of hiPSC derived hepatocytes for conducting mechanistic toxicity testing by image based high content analysis (HCA). The hiPSC derived hepatocytes were exposed to drugs known to cause hepatotoxicity through steatosis and phospholipidosis, measuring several endpoints representing different mechanisms involved in drug induced hepatotoxicity. The hiPSC derived hepatocytes were benchmarked to the HepG2 cell line and generated robust HCA data with low imprecision between plates and batches. The different parameters measured were detected at subcytotoxic concentrations and the order of which the compounds were categorized (as severe, moderate, mild, or nontoxic) based on the degree of injury at isomolar concentration corresponded to previously published data. Taken together, the present study shows how hiPSC derived hepatocytes can be used as a platform for screening drug induced hepatotoxicity by HCA.
url http://dx.doi.org/10.1155/2016/2475631
work_keys_str_mv AT arvindpradip highcontentanalysisofhumanpluripotentstemcellderivedhepatocytesrevealsdruginducedsteatosisandphospholipidosis
AT daniellasteel highcontentanalysisofhumanpluripotentstemcellderivedhepatocytesrevealsdruginducedsteatosisandphospholipidosis
AT susannajacobsson highcontentanalysisofhumanpluripotentstemcellderivedhepatocytesrevealsdruginducedsteatosisandphospholipidosis
AT gustavholmgren highcontentanalysisofhumanpluripotentstemcellderivedhepatocytesrevealsdruginducedsteatosisandphospholipidosis
AT magnusingelmansundberg highcontentanalysisofhumanpluripotentstemcellderivedhepatocytesrevealsdruginducedsteatosisandphospholipidosis
AT petersartipy highcontentanalysisofhumanpluripotentstemcellderivedhepatocytesrevealsdruginducedsteatosisandphospholipidosis
AT petterbjorquist highcontentanalysisofhumanpluripotentstemcellderivedhepatocytesrevealsdruginducedsteatosisandphospholipidosis
AT ingerjohansson highcontentanalysisofhumanpluripotentstemcellderivedhepatocytesrevealsdruginducedsteatosisandphospholipidosis
AT josefinaedsbagge highcontentanalysisofhumanpluripotentstemcellderivedhepatocytesrevealsdruginducedsteatosisandphospholipidosis
_version_ 1725669971240943616